View Older Stories View More Recent Stories

Feb 14, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance for Priority of Application for Augtyro
Feb 14, 2024 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or M
Feb 12, 2024 06:59AM Bristol-Myers Squibb (BMY) and RayzeBio (RYZB) Announce Expiration of HSR Act Waiting Period
Feb 12, 2024 06:59AM Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
Feb 7, 2024 06:59AM Bristol-Myers Squibb (BMY) Announced Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Canc
Feb 7, 2024 06:59AM Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lun
Feb 5, 2024 09:20AM Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
Feb 5, 2024 09:00AM Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
Feb 5, 2024 07:02AM Bristol-Myers (BMY), 2seventy bio (TSVT) announce FDA will convene meeting of ODAC on March 15 to review data supporting sBLA for Abecma
Feb 5, 2024 06:59AM Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
Feb 2, 2024 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
Jan 30, 2024 09:15AM Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Jan 30, 2024 06:59AM Bristol-Myers Squibb (BMY) Reports Breyanzi Regulatory Applications in FL and MCL Accepted in the U.S. and Japan
Jan 30, 2024 06:59AM Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Ma
Jan 29, 2024 05:54AM Bristol-Myers Squibb (BMY) Reports Subcutaneous Nivolumab Shows Noninferiority Compared to Intravenous Opdivo
Jan 27, 2024 10:00AM Subcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
Jan 26, 2024 07:14AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma in Earlier Lines of Therapy for Triple-Class Exposed R/R MM
Jan 26, 2024 07:13AM Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Jan 23, 2024 08:33AM Bristol-Myers Squibb (BMY) Completes Acquisition of Mirati Therapeutics (MRTX)
Jan 23, 2024 08:30AM Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Jan 22, 2024 05:05PM Bristol-Myers Squibb (BMY) Reports Eight-Year Data for Opdivo Plus Yervoy Continued to Demonstrate Longest Survival Benefit vs. Sunitinib
Jan 22, 2024 05:05PM Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Ren
Jan 22, 2024 05:01PM Bristol-Myers Squibb (BMY) and Exelixis (EXEL) Announce Opdivo with CABOMETYX Demonstrated Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial
Jan 22, 2024 05:00PM Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell
Jan 20, 2024 10:00AM Opdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Me
Jan 17, 2024 06:59AM Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
Jan 2, 2024 06:59AM Bristol-Myers Squibb (BMY) Reports EMA Validation of Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid
Jan 2, 2024 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positiv
Dec 26, 2023 07:13AM Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Dec 26, 2023 07:00AM Bristol-Myers Squibb (BMY) Announces Acquisition of RayzeBio (RYZB) for $62.50 Per Share, $4.1 Billion
Dec 26, 2023 06:59AM  Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Dec 22, 2023 09:13AM PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
Dec 22, 2023 06:59AM Bristol-Myers Squibb (BMY) to Acquire Karuna Therapeutics (KRTX) for $330/sh or $14B
Dec 22, 2023 06:59AM Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
Dec 22, 2023 06:59AM Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
Dec 20, 2023 04:16PM Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
Dec 15, 2023 04:55PM Bristol-Myers Squibb (BMY) Provides Update on RELATIVITY-123 Trial of Combination of Nivolumab and Relatlimab
Dec 15, 2023 04:54PM Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS
Dec 15, 2023 06:59AM Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
Dec 12, 2023 03:28AM Bristol-Myers Squibb (BMY) Announces Data from Diverse Multiple Myeloma Pipeline
Dec 12, 2023 03:22AM Bristol-Myers Squibb (BMY) and 2seventy bio (TSVT) Report Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple
Dec 11, 2023 09:00PM Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Dec 11, 2023 08:30PM Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Dec 11, 2023 07:30PM Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Dec 11, 2023 04:15PM Bristol-Myers Squibb (BMY) and SystImmune Enter Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
Dec 11, 2023 04:15PM SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
Dec 11, 2023 04:01AM Bristol-Myers Squibb (BMY) Reports Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl
Dec 11, 2023 03:40AM Bristol-Myers Squibb (BMY) Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi
Dec 10, 2023 09:26PM Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed o
Dec 9, 2023 05:00PM Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk
View More Recent Stories View Older Stories